News

Novo Nordisk hopes to see US Wegovy sales recover soon
Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the ...
Fierce Pharma1h
Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
BioSpace52m
Novo Vows Smoother Market Waters for Wegovy—But Analysts Are Skeptical
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...
Novo Nordisk shares up on hopes for US Wegovy recovery after forecasts cut
Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy ...
How copycats of Wegovy, Zepbound created a billion-dollar market
Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
Novo Nordisk Gains as CFO Touts Wegovy’s Rebound Potential
Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving ...
BioSpace2d
Novo’s Wegovy Inches Closer to Becoming First FDA-Approved GLP-1 Weight-Loss Pill
The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...